By Fineline Cube 
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its controlled subsidiary, Fosun Pharma Industrial, together with eleven other investors, has signed a partnership agreement to create a new target fund. Fosun Pharma Industrial will serve as a Limited Partner (LP) and contribute RMB 100 million in cash.
Fund Structure & Capital Raise
- Target Capital: RMB 1 billion
- General Partner (GP): China Resources Pharmaceutical Technology
- Key Limited Partners: Boya Bio‑Pharmaceutical, Dong‑E‑E‑Jiao, Jiangzhong Pharmaceutical, China Resources Double‑Crane, and others
Investment Focus
The fund will prioritize strategic emerging segments, including:
- Chemical innovative drugs
- Biologics (vaccines and other biologic agents)
- High‑end medical devices (including in‑vitro diagnostics)
- Traditional Chinese medicine tonics
- Synthetic biology
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech